Oncology outcomes
Does ovarian-cancer clone diversity predict death?
Open access · cc by · source: Europe PMC
In 14 women with high-grade serous ovarian cancer, high clonal expansion predicted worse PFS (10.1 vs 12.7 mo) and OS (23.5 vs 42.6 mo); an NF1-deleted relapse clone was already detectable before chemotherapy.
Study at a glance
- Design
- Cohort — Phylogenetic MEDICC analysis of spatially/temporally separated HGSOC samples from women receiving platinum chemotherapy (CTCR-OV03/04)
- N
- N=14 · 135 samples from 14 patients in the phylogenetic/survival analysis; 177 arrays from 18 patients profiled, 17 remaining after QC
- Population
- Women with high-grade serous ovarian cancer on platinum-based chemotherapy in CTCR-OV03/04
- Outcome
- Clonal-expansion (CE) index vs progression-free and overall survival; origin of relapse clones
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Median CE was 0.74 (IQR 0.66–1.15). CE-high tumors had PFS 10.1 vs 12.7 mo (p=0.009) and OS 23.5 vs 42.6 mo (p=0.003); CE-high remained independently prognostic. Bootstrapped HRs were 7.1 (PFS) and 11.4 (OS). An NF1 deletion marking relapse was already 5% and 26% of pre-treatment samples.
Methodology
Used MEDICC on whole-genome copy-number profiles from 135 spatially and temporally separated samples in 14 HGSOC patients on platinum therapy (CTCR-OV03/04; median follow-up 31 mo). Dichotomized clonal expansion (CE) at the median and related it to PFS/OS; digital PCR tracked an NF1 deletion at relapse.
Limitations
n=14 cannot precisely size the hazard; CE as a continuous variable was not significant in multivariable models, so the median split is a small-cohort signal, not a ready clinical test.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
- A 22-gene classifier flags early metastasis after prostatectomy
- HDAC2 IHC tracks shorter PSA relapse in prostate cancer
- Five integrated genomic subgroups track prostate-cancer relapse risk
- Does mixed DNA inside a head-and-neck tumor predict death?